#357 ‒ A new era of longevity science: models of aging, human trials of rapamycin, biological clocks, promising compounds, and lifestyle interventions | Brian Kennedy, Ph.D.

In this episode of The Drive, Peter Attia interviews Brian Kennedy, a biologist and leader in aging research. They discuss Kennedy's move to Singapore to conduct larger clinical aging studies, the shift in longevity research funding around 2017, and different concepts of aging. The conversation covers rapamycin testing in humans, aging biomarkers, promising compounds like alpha-ketoglutarate and urolethin A, and combining lifestyle factors with pharmacology. They explore the hallmarks of aging, the role of mTOR, and the challenges of defining and targeting aging, including the linear accumulation of damage versus the exponential increase in mortality. The discussion also delves into the potential of epigenetic clocks, the inevitability of certain diseases, and the importance of basic science research in aging and longevity.